Select language:
On this page


    Last updated: June 2021


    Prescription under medical supervision


    Therapeutic action

    • First line antituberculosis antibacterial (sterilising and bactericidal activity)


    • Tuberculosis, in combination with other antituberculosis antibacterials

    Forms and strengths

    • 400 mg tablet
    • 150 mg dispersible tablet


    • Child under 30 kg: 35 mg/kg (30 to 40 mg/kg) once daily
    • Child 30 kg and over and adult: 25 mg/kg (20 to 30 mg/kg) once daily
    • Do not exceed 2 g daily.
    • Patient with renal impairment: 25 mg/kg 3 times weekly


    • According to protocol

    Contra-indications, adverse effects, precautions

    • Do not administer to patients with hypersensitivity to pyrazinamide, severe hepatic impairment or severe gout.
    • May cause: gout and arthralgias, hepatotoxicity, photosensitivity (limit sun exposure), rash, gastrointestinal disturbances, hypersensitivity reactions.
    • Monitor liver function in patients with known hepatic disease.
    • If signs of hepatotoxicity (e.g. jaundice) develop, pyrazinamide should be discontinued until symptoms resolve.
    • Pregnancy: no contra-indication
    • Breast-feeding: no contra-indication


    • For patients on first-line antituberculosis treatment, pyrazinamide is given as part of a fixed dose combination.


    –  Below 25 °C